Pharmaceuticals
AstraZeneca stock jumps after surprise trial win for lung disease drug where rivals have failed
AstraZeneca‘s stock jumped nearly 5% after Britain’s most valuable company said its experimental lung disease medicine met its target in two late-stage clinical trials. The respiratory treatment tozorakimab, reduced flare-ups of chronic obstructive pulmonary disease (COPD) in both former smokers and in the overall population versus placebo, the company said. “This marks a notable shift […]
Read More
Novartis shells out $2 billion for immunology biotech Excellergy, in second multi-billion dollar deal in a week
A sign of Swiss pharmaceutical giant Novartis is seen on the top of a building at Novartis Campus in Basel, northern Switzerland, on Sept. 9, 2025. Fabrice Coffrini | AFP | Getty Images Novartis is planning to buy U.S.-based biotech Excellergy for up to $2 billion, betting on a next-generation allergy treatment that may prove […]
Read More
Merck to buy Terns Pharmaceuticals for $6.7 billion to boost cancer pipeline
Pharma giant Merck is buying U.S. biotech firm Terns Pharmaceuticals for $6.7 billion to boost its oncology pipeline, the company said Wednesday. This is the third multibillion-dollar acquisition for Merck over the past year as the company looks to bulk up its portfolio before its best-selling cancer drug Keytruda loses key patent protection in 2028. […]
Read More
Pfizer to seek FDA approval for Lyme disease vaccine candidate despite trial miss
Thomas Fuller | Nurphoto | Getty Images Pfizer on Monday said it will seek regulatory approval for a Lyme disease vaccine candidate despite the shot failing a late-stage trial. Pfizer said the vaccine missed the trial’s statistical goal because not enough people in the study contracted Lyme disease to be confident in the results. Still, […]
Read More
FDA approves higher dose version of weight loss drug Wegovy as Novo Nordisk tries to win back market share
The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, Copenhagen, Denmark, Feb. 4, 2026. Tom Little | Reuters The Food and Drug Administration on Thursday approved a higher dose version of Novo Nordisk‘s blockbuster weight loss injection Wegovy, as the company pushes to win back market share from […]
Read More
Eli Lilly’s next-generation obesity drug retatrutide clears first late-stage diabetes trial
Eli Lilly on Thursday said its next-generation obesity drug retatrutide cleared its first late-stage trial on Type 2 diabetes patients, helping them manage their blood sugar levels and lose weight. The drug lowered hemoglobin A1c — a key measure of blood sugar levels — by an average of 1.7% to 2% across different doses at […]
Read More
Eli Lilly catches a downgrade as HSBC warns of an overhyped obesity drug market
HSBC analysts just slashed their recommendation on the world’s most valuable pharmaceutical company, Eli Lilly, signaling a potential cooling period for the red-hot obesity drug trade that has come to dominate market narratives of the sector. Analysts led by Rajesh Kumar downgraded Lilly to Reduce from Hold, cutting their target price to $850 from $1,070, […]
Read More
FDA approves leucovorin as first drug for rare genetic disorder, after touting it as autism treatment
FILE PHOTO: The headquarters of the U.S. Food and Drug Administration (FDA) is seen in Silver Spring, Maryland November 4, 2009. Jason Reed | Reuters The Food and Drug Administration on Tuesday approved a decades-old prescription vitamin called leucovorin as the first treatment for a rare genetic disorder in certain adults and children. The move […]
Read More
Hims & Hers shares surge 50% after Novo Nordisk drops patent infringement case over compounded weight loss drugs
Novo Nordisk has dropped its legal case against telehealth provider Hims & Hers over patent infringement, after the two companies agreed Hims would sell Novo’s branded medicines through its platform. “We have decided to drop the current court proceedings and, of course, we reserve to bring that back if need be, but I don’t foresee […]
Read More
Zealand’s stock falls 35% after disappointing drug result. Its CEO tells CNBC people need to focus less on the ‘weight loss Olympics’
Wegovy is produced by pharmaceutical company Novo Nordisk and has been approved for specifically for chronic weight management in adults and adolescents. (Photo by Steve Christo – Corbis/Corbis via Getty Images) Steve Christo – Corbis | Corbis News | Getty Images The chief executive of drugmaker Zealand Pharma sought to calm investors about the latest […]
Read More